Because we observed that serum IL-2 was sustained specifically in MA TMZ-treated mice but not those treated with NMA TMZ, we sought to determine whether myeloablative TMZ would be superior to the previously-published NMA TMZ dose with regard to its ability to augment antitumor immunotherapy against experimental brain tumors. Here, IL2 is linked to brain neoplasm.